C4 Therapeutics (CCCC) Insider Trading & Ownership $6.04 +0.07 (+1.17%) (As of 11/7/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends C4 Therapeutics (NASDAQ:CCCC) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.55%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$115,735.20Number OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$53,121.80 Get CCCC Insider Trade Alerts Want to know when executives and insiders are buying or selling C4 Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CCCC Insider Buying and Selling by Quarter Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. C4 Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/8/2023Utpal KoppikarDirectorBuy5,667$5.60$31,735.20 4/12/2022Andrew HirschCEOBuy10,000$8.40$84,000.00 12/17/2021Malcolm SalterDirectorSell755$30.25$22,838.75 11/19/2021Malcolm SalterDirectorSell755$40.11$30,283.05 (Data available from 1/1/2013 forward) CCCC Insider Trading Activity - Frequently Asked Questions Who is on C4 Therapeutics's Insider Roster? The list of insiders at C4 Therapeutics includes Andrew Hirsch, Malcolm Salter, and Utpal Koppikar. Learn more on insiders at CCCC. What percentage of C4 Therapeutics stock is owned by insiders? 8.55% of C4 Therapeutics stock is owned by insiders. Learn more on CCCC's insider holdings. Which C4 Therapeutics insiders have been buying company stock? The following insider purchased CCCC shares in the last 24 months: Utpal Koppikar ($31,735.20). How much insider buying is happening at C4 Therapeutics? Insiders have purchased a total of 5,667 CCCC shares in the last 24 months for a total of $31,735.20 bought. C4 Therapeutics Key ExecutivesMr. Andrew J. Hirsch M.B.A. (Age 53)CEO, President & Director Compensation: $971kDr. Kenneth C. Anderson M.D. (Age 73)Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board Compensation: $39.03kDr. Stewart Fisher (Age 57)Chief Scientific Officer Compensation: $657.34kMr. Scott N. Boyle M.B.A. (Age 46)Ph.D., Chief Business Officer Compensation: $672.78kDr. Nathanael S. Gray Ph.D.Co-Founder & Member of Scientific Advisory BoardMs. Kendra AdamsChief Financial OfficerMr. Mark Mossler (Age 51)Chief Accounting Officer Ms. Jolie M. Siegel J.D. (Age 47)Chief Legal Officer & Corporate Secretary Compensation: $610.4kMs. Kelly A. Schick (Age 44)Chief People Officer Dr. Isabel Chiu Ph.D.Senior Vice President of Strategic Alliances & Business Development More Insider Trading Tools from MarketBeat Related Companies Alector Insider Buying Inhibrx Insider Buying Rocket Pharmaceuticals Insider Buying Intellia Therapeutics Insider Buying ARS Pharmaceuticals Insider Buying Xencor Insider Buying Avadel Pharmaceuticals Insider Buying Ardelyx Insider Buying Arcus Biosciences Insider Buying Disc Medicine Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics PartnersInsider Selling is not a Signal to Start Selling Gartner Stock2 Stocks to Buy and 1 to Sell - Smart Moves for Investors This page (NASDAQ:CCCC) was last updated on 11/8/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump’s Victory Just Kicked the Door Open to a…This story is about a division that has been splitting America apart at the seams for the past three and a hal...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.